Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...

After the FDA’s first-ever public listening meeting on data-sharing in the cell and gene therapy space, new draft guidance ...

Scholar Rock Holding () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful inves ...

Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal ...

Kids with Duchenne muscular dystrophy and their families deserve the chance to decide their own future.

New research suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks, ...

Research at Clarkson University is helping people with hypermobile Ehlers-Danlos syndrome (hEDS) move with less pain and more confidence. The study, published in the Journal of Multidisciplinary ...

Objective To examine the effect of exercise during the first year postpartum on pelvic floor disorders and diastasis recti abdominis. Design Systematic review with random effects meta-analysis. Data ...

Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid ...

Insmed has launched a Phase 1 clinical trial testing INS1202, an experimental gene therapy for ALS. INS1202 is designed to reduce levels of the toxic SOD1 protein implicated in some ALS cases, ...